• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    26 Stocks Moving in Monday's Pre-Market Session

    4/25/22 6:13:00 AM ET
    $AIM
    $ARDX
    $BRQS
    $CANG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIM alert in real time by email

    Gainers

    • ERYTECH Pharma S.A. (NASDAQ:ERYP) shares rose 88.4% to $2.30 in pre-market trading. Erytech Pharma recently announced publication of results from Eryapasse Phase 2 trial as treatment for hypersensitive ALL in the British Journal of Haematology.
    • Cango Inc. (NYSE:CANG) rose 23.7% to $2.92 in pre-market trading. Cango, last month, reported worse-than-expected Q4 EPS and sales results.
    • Aclarion, Inc. (NASDAQ:ACON) rose 15.7% to $3.15 in pre-market trading. The company, on Friday, priced its IPO at $4.35 per share.
    • TC Biopharm (Holdings) Plc (NASDAQ:TCBP) rose 15% to $1.30 in pre-market trading. TC Biopharm recently registered the U.K. trademark CryoTC for its proprietary process for freezing and thawing its lead oncology product, OmnImmune.
    • AIM ImmunoTech Inc. (NYSE:AIM) rose 14.8% to $1.17 in pre-market trading. AIM ImmunoTech recently issued summary of Ampligen data.
    • Cenntro Electric Group Limited (NASDAQ:CENN) rose 14.1% to $1.94 in pre-market trading after gaining around 7% on Friday.
    • Quantum Computing, Inc. (NASDAQ:QUBT) rose 11.8% to $1.99 in pre-market trading after declining around 5% on Friday.
    • Silicon Motion Technology Corporation (NASDAQ:SIMO) rose 9% to $84.00 in pre-market trading after Bloomberg reported that the company exploring a potential sale amid takeover interest.
    • Shift Technologies, Inc. (NASDAQ:SFT) rose 9.1% to $1.68 in pre-market trading. Shift is expected to report its financial results for the first quarter 2022, on May 10, 2022.
    • XORTX Therapeutics Inc. (NASDAQ:XRTX) rose 8.9% to $1.96 in pre-market trading. XORTX Therapeutics, last month, announced the submission of a Patent Cooperation Treaty patent application seeking international patent protection for the patent entitled "Compositions and Methods for Enhancing Anti-Vi."
    • Genocea Biosciences, Inc. (NASDAQ:GNCA) rose 8.8% to $0.4550 in pre-market trading.
    • Zosano Pharma Corporation (NASDAQ:ZSAN) shares rose 7.2% to $2.38 in pre-market trading after declining around 7% on Friday.
    • New Concept Energy, Inc. (NYSE:GBR) rose 6.9% to $2.93 in pre-market trading.
    • Ardelyx, Inc. (NASDAQ:ARDX) rose 6.9% to $0.7998 in pre-market trading. Ardelyx recently amended its license agreement, initially executed in 2017, granting Kyowa Kirin exclusive rights to develop and commercialize Ardelyx's tenapanor for cardiorenal diseases, including hyperphosphatemia, in Japan.

    Don’t forget to check out our premarket coverage here .

    Losers

    • Cypress Environmental Partners, L.P. (NYSE:CELP) fell 27.5% to $0.4666 in pre-market trading after the company said an affiliate of Argonaut Private Equity has acquired 100% of Cypress’s senior secured debt from the seven existing lenders.
    • Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) fell 15.4% to $1.92 in pre-market trading. Vallon Pharmaceuticals shares jumped more than 100% on Friday after the company announced a review of strategic alternatives.
    • Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT) shares fell 13.7% to $1.55 in pre-market trading after dropping 22% on Friday. The company recently announced it will present new data on JATENZO at the Androgen Society 4th Annual Meeting.
    • KemPharm, Inc. (NASDAQ:KMPH) shares fell 13.3% to $4.10 in pre-market trading after jumping around 12% on Friday. The company recently doses first subject in Phase 1 clinical trial evaluating cardiovascular safety of serdexmethylphenidate.
    • Moving iMage Technologies, Inc. (NASDAQ:MITQ) fell 12.5% to $1.39 in pre-market trading. Moving iMage Technologies shares climbed 38% on Friday after the company and SNDBX announced a strategic partnership to bring the full theatre experience to the gaming and e-Sports market.
    • Forge Global Holdings, Inc. (NYSE:FRGE) fell 12.4% to $12.30 in pre-market trading after climbing 20% on Friday.
    • Cyngn Inc. (NASDAQ:CYN) fell 11.5% to $2.38 in pre-market trading after climbing around 27% on Friday. Cyngn recently announced the official launch of DriveMod Kit, a turnkey autonomous vehicle solution
    • Borqs Technologies, Inc. (NASDAQ:BRQS) fell 10.3% to $0.2960 in pre-market trading after dropping 8% on Friday.
    • Koninklijke Philips N.V. (NYSE:PHG) shares fell 9.7% to $27.39 in pre-market trading. Philips reported a first-quarter FY22 sales growth of 2.6% year-on-year to €3.9 billion.
    • Wheels Up Experience Inc. (NYSE:UP) fell 8.4% to $2.77 in pre-market trading. Wheels Up Experience is expected to release its Q1 financial results after the market closes on Thursday, May 12, 2022.
    • JE Cleantech Holdings Limited (NASDAQ:JCSE) fell 8.4% to $17.40 in pre-market trading. The company, on Friday, priced its IPO at $4 per share.
    • Taseko Mines Limited (NYSE:TGB) shares fell 8% to $1.85 in pre-market trading after dropping 5% on Friday.
    Get the next $AIM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIM
    $ARDX
    $BRQS
    $CANG

    CompanyDatePrice TargetRatingAnalyst
    Silicon Motion Technology Corporation
    $SIMO
    1/22/2026Outperform
    William Blair
    Quantum Computing Inc.
    $QUBT
    1/15/2026$22.00Buy
    Rosenblatt
    Ardelyx Inc.
    $ARDX
    1/9/2026Neutral → Overweight
    Piper Sandler
    Quantum Computing Inc.
    $QUBT
    12/17/2025$12.00Neutral
    Wedbush
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    12/17/2025Sector Perform
    RBC Capital Mkts
    Forge Global Holdings Inc.
    $FRGE
    12/12/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Forge Global Holdings Inc.
    $FRGE
    11/7/2025Overweight → Neutral
    Piper Sandler
    Quantum Computing Inc.
    $QUBT
    9/18/2025$24.00Buy
    Lake Street
    More analyst ratings

    $AIM
    $ARDX
    $BRQS
    $CANG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AIM ImmunoTech Announces Commencement of Rights Offering

    OCALA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) – AIM ImmunoTech Inc. ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced that it has commenced its previously disclosed rights offering (the "Rights Offering").  Pursuant to the Rights Offering, the Company is distributing to all holders of record of the Company's common stock, par value $0.001 per share ("Common Stock"), and to holders of certain options and warrants that have the right to participate in the Rights O

    2/11/26 8:30:00 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEISMIC consortium secures EUR 23.5 million IHI grant to pioneer next-generation minimally invasive brain treatments

    February 11, 2026 Co-funded by the EU's Innovative Health Initiative (IHI), the research consortium is coordinated by Philips, together with Erasmus MC as academic lead, and will combine advanced medical imaging and minimally invasive techniques to transform treatment of bleeding and tumors in the brainFive-year research program with total budget of EUR 38.4 million includes eight clinical studies to validate technical solutions for minimally invasive neurosurgery Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced that the SEISMIC research consortium, coordinated by Philips, together with Erasmus MC as academic lead, has

    2/11/26 4:00:00 AM ET
    $PHG
    Medical Electronics
    Health Care

    Philips proposes to re-appoint CEO Roy Jakobs

    February 10, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced that Roy Jakobs is proposed to be re-appointed as its President/Chief Executive Officer and member of the Board of Management. The decision to propose the re-appointment of Roy Jakobs reflects the Supervisory Board's recognition of the progress made since 2022 and its confidence in his leadership as Philips enters the next phase of driving profitable growth. The proposal will be submitted for approval at the upcoming Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. "Roy Jakobs has demonstrated clear leadership, strong execution

    2/10/26 12:55:00 AM ET
    $PHG
    Medical Electronics
    Health Care

    $AIM
    $ARDX
    $BRQS
    $CANG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chemerow David I. was granted 2,800 shares (SEC Form 4)

    4 - AIM ImmunoTech Inc. (0000946644) (Issuer)

    2/6/26 5:03:20 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Rodriques Kelly was granted 30,035 shares, increasing direct ownership by 7% to 448,791 units (SEC Form 4)

    4 - Forge Global Holdings, Inc. (0001827821) (Issuer)

    1/30/26 4:23:44 PM ET
    $FRGE
    Investment Bankers/Brokers/Service
    Finance

    Chief Financial Officer Nevin James was granted 15,234 shares, increasing direct ownership by 64% to 38,929 units (SEC Form 4)

    4 - Forge Global Holdings, Inc. (0001827821) (Issuer)

    1/30/26 4:23:04 PM ET
    $FRGE
    Investment Bankers/Brokers/Service
    Finance

    $AIM
    $ARDX
    $BRQS
    $CANG
    SEC Filings

    View All

    SEC Form EFFECT filed by AIM ImmunoTech Inc.

    EFFECT - AIM ImmunoTech Inc. (0000946644) (Filer)

    2/11/26 12:15:22 AM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form S-1/A filed by AIM ImmunoTech Inc.

    S-1/A - AIM ImmunoTech Inc. (0000946644) (Filer)

    2/10/26 4:35:37 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Koninklijke Philips N.V. NY Registry Shares

    6-K - KONINKLIJKE PHILIPS NV (0000313216) (Filer)

    2/10/26 7:58:39 AM ET
    $PHG
    Medical Electronics
    Health Care

    $AIM
    $ARDX
    $BRQS
    $CANG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    10/20/23 4:37:52 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:43:04 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZA™ issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:37:08 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIM
    $ARDX
    $BRQS
    $CANG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Silicon Motion

    William Blair initiated coverage of Silicon Motion with a rating of Outperform

    1/22/26 8:30:26 AM ET
    $SIMO
    Semiconductors
    Technology

    Rosenblatt initiated coverage on Quantum Computing with a new price target

    Rosenblatt initiated coverage of Quantum Computing with a rating of Buy and set a new price target of $22.00

    1/15/26 8:40:11 AM ET
    $QUBT
    Computer Software: Prepackaged Software
    Technology

    Ardelyx upgraded by Piper Sandler

    Piper Sandler upgraded Ardelyx from Neutral to Overweight

    1/9/26 8:23:44 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIM
    $ARDX
    $BRQS
    $CANG
    Financials

    Live finance-specific insights

    View All

    Wheels Up Announces Date of Fourth Quarter 2025 Earnings Release

    ATLANTA, Feb. 5, 2026 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that it will release its fourth quarter 2025 financial results on Thursday, February 19, 2026. Earnings materials will be available on the Wheels Up investor relations website at investors.wheelsup.com. About Wheels Up Wheels Up is a leading global provider of on-demand private aviation with a large, diverse fleet and a network of safety-vetted charter operators, all committed to safety and service. Customers access charter and membership programs and premium commercial travel benefits th

    2/5/26 8:00:00 AM ET
    $UP
    Transportation Services
    Consumer Discretionary

    Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

    WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 19, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2025. The call will include commentary from members of the Ardelyx Executive Leadership Team including Mike Raab, President and Chief Executive Officer, Sue Hohenleitner, Chief Financial Officer, Eric Foster, Chief Commercial Officer, and Laura

    2/5/26 8:00:00 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Silicon Motion Announces Results for the Fourth Quarter and Year Ended December 31, 2025

    Business Highlights Fourth quarter of 2025 sales increased 15% Q/Q and increased 46% Y/Y SSD controller sales: 4Q of 2025 increased 25% to 30% Q/Q and increased 35% to 40% Y/YeMMC+UFS controller sales: 4Q of 2025 increased 0% to 5% Q/Q and increased 50% to 55% Y/YSSD solutions sales: 4Q of 2025 increased 125% to 130% Q/Q and increased 110% to 115% Y/Y Announced annual cash dividend of $2.00 per American Depositary Share ("ADS") Financial Highlights  4Q 2025 GAAP4Q 2025 Non-GAAP*•   Net sales$278.5 million (+15% Q/Q, +46% Y/Y)$278.5 million (+15% Q/Q, +46% Y/Y)•   Gross margin49.1%49.2%•   Operating margin11.4%19.3%•   Earnings per diluted ADS$1.41$1.26  Full Year 2025 GAAPFull Year 2025 N

    2/3/26 6:00:00 PM ET
    $SIMO
    Semiconductors
    Technology

    $AIM
    $ARDX
    $BRQS
    $CANG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Nevin James bought $44,168 worth of shares (1,950 units at $22.65), increasing direct ownership by 9% to 24,124 units (SEC Form 4)

    4 - Forge Global Holdings, Inc. (0001827821) (Issuer)

    8/7/25 4:55:46 PM ET
    $FRGE
    Investment Bankers/Brokers/Service
    Finance

    Director Mott David M bought $725,880 worth of shares (200,000 units at $3.63), increasing direct ownership by 7% to 2,896,871 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    6/18/25 9:28:07 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mott David M bought $737,260 worth of shares (200,000 units at $3.69), increasing direct ownership by 8% to 2,696,871 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    6/11/25 9:40:28 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIM
    $ARDX
    $BRQS
    $CANG
    Leadership Updates

    Live Leadership Updates

    View All

    Philips proposes to re-appoint CEO Roy Jakobs

    February 10, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced that Roy Jakobs is proposed to be re-appointed as its President/Chief Executive Officer and member of the Board of Management. The decision to propose the re-appointment of Roy Jakobs reflects the Supervisory Board's recognition of the progress made since 2022 and its confidence in his leadership as Philips enters the next phase of driving profitable growth. The proposal will be submitted for approval at the upcoming Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. "Roy Jakobs has demonstrated clear leadership, strong execution

    2/10/26 12:55:00 AM ET
    $PHG
    Medical Electronics
    Health Care

    Cango Inc. Completes Bitcoin Sale to Strengthen Financial Position and Advance AI Transformation

    DALLAS, Feb. 9, 2026 /PRNewswire/ -- Cango Inc. (NYSE:CANG) ("Cango" or the "Company"), a leading Bitcoin miner leveraging its global operations to develop an integrated energy and AI compute platform, today announced that, based on a comprehensive assessment of current market conditions and upon approval of the Company's Board of Directors, it completed the sale of 4,451 Bitcoin on the open market during the past weekend, which were settled directly in USDT for aggregate net proceeds of approximately US$305 million in equivalent value. The full amount of the USDT proceeds has been utilized to partially repay a Bitcoin-collateralized loan.

    2/9/26 6:26:00 AM ET
    $CANG
    Computer Software: Prepackaged Software
    Technology

    XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

    CALGARY, Alberta, Feb. 04, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that further to its press release of October 17, 2025 and an update on December 31, 2025, the Company has entered into an extension agreement with Vectus Biosystems Limited ("Vectus") to allow further time to complete the acquisition of the Renal Anti-Fibrotic Therapeutic Program from Vectus (the "Acquisition"). The term sheet entered into October 17th (the "Term Sheet") to acquire the novel new chemical

    2/4/26 6:00:00 PM ET
    $XRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIM
    $ARDX
    $BRQS
    $CANG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc

    SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

    11/14/24 4:41:42 PM ET
    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Wheels Up Experience Inc.

    SC 13D/A - Wheels Up Experience Inc. (0001819516) (Subject)

    11/14/24 4:30:05 PM ET
    $UP
    Transportation Services
    Consumer Discretionary